Author Contributions: Dr Timmerman had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis
Study concept and design: Timmerman, Galvin, Bradley, Johnstone, Fowler, Choy.
Acquisition of data: Timmerman, Michalski, Straube, Bradley, Fakiris, Bezjak, Videtic, Gore.
Analysis and interpretation of data: Timmerman, Paulus, Michalski, Straube, Bradley, Bezjak, Fowler.
Drafting of the manuscript: Timmerman, Paulus.
Critical revision of the manuscript for important intellectual content: Timmerman, Galvin, Michalski, Straube, Bradley, Fakiris, Bezjak, Videtic, Johnstone, Fowler, Gore, Choy.
Statistical analysis: Paulus.
Obtained funding: Timmerman.
Administrative, technical or material support: Timmerman, Paulus, Galvin, Michalski, Straube, Bradley, Fakiris, Gore.
Study supervision: Timmerman, Johnstone, Choy.
Financial Disclosures: Dr Timmerman reported receiving a research grant for technology development from both Varian Medical Systems (Palo Alto, California) and Elekta Oncology (Stockholm, Sweden). Both of these companies manufacture equipment used in the performance of stereotactic body radiation therapy. In addition, he reported receiving grants from the US National Institutes of Health and Department of Defense to carry out separate protocols using stereotactic radiotherapy in both lung and prostate cancer. None of the other authors reported any financial disclosures.
Funding/Support: This work was funded by grants RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115 from the National Cancer Institute and grant U24 CA 81647 from the Advanced Technology Consortium.
Role of the Sponsor: The sponsors initially approved the study concept and the original protocol, required regular updates regarding protocol accrual and data safety monitoring, and provided funds to each participating center for each protocol accrual. The sponsors did not have any role in the analysis or interpretation of the data or in the preparation, review, or approval of the manuscript.
Additional Contributions: We thank Linda Walters-Page, BS, salaried employee at the Radiation Therapy Oncology Group, for her oversight of the trial including submissions, processing amendments, and responding to site queries.